5th Annual Healthcare Conference
Conf Logo


Essner Robert A. Essner
Former Chairman & CEO  Wyeth

Executive-in-Residence Columbia Business School
Ludwig Edward J. Ludwig ('75)
Chairman & CEO
BD (Becton Dickinson)


Robert A. Essner
Former Chairman & CEO, Wyeth

Robert Essner, Retired Chairman of the Board, joined Wyeth in 1989 following thirteen years with Sandoz Pharmaceuticals. In 1993 he became President of Wyeth-Ayerst Laboratories responsible for the domestic pharmaceutical business.  In 1997, Mr. Essner was named President of Wyeth-Ayerst Global Pharmaceuticals and assumed responsibility for the global pharmaceutical business.  The same year, he was elected to the position of Executive Vice President and member of the Board of Directors, Wyeth.  In 2000, he was elected President and Chief Operating Officer.  Mr. Essner was elected Chief Executive Officer in May 2001 and Chairman in January 2003.    

A graduate of Miami University, Oxford, Ohio, Mr. Essner received a master’s degree from the University of Chicago.
Mr. Essner was Chairman of the Children’s Health Fund Corporate Council for 13 years, and is presently on the Fund’s Board of Directors.  He is also as a member of the Business Roundtable and Business Council.  In addition, he is a member of the Board of Directors of Massachusetts Mutual Life Insurance Company and Lincoln Center for the Performing Arts.  Mr. Essner is past Chairman of the Pharmaceutical Research & Manufacturers of America.

Mr. Essner lives in New Jersey and New York with his wife, Anne, and their family.


Edward J. Ludwig ('75)
Chairman & CEO, BD (Becton Dickinson)

Edward J. Ludwig serves as Chairman of the Board, President and Chief Executive Officer of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey.  Mr. Ludwig joined BD in 1979 as a senior financial analyst and was named Chief Financial Officer in August 1995, President in May 1999 and Chief Executive Officer in January 2000. He was elected Chairman in February 2002.

Prior to joining BD, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now Pricewaterhouse Coopers) and as a financial and strategic analyst at Kidde, Inc.

Active in philanthropic efforts, Mr. Ludwig is a member of the Board of Trustees of the College of the Holy Cross.  He is a member and past Chair of the Health Advisory Board for the Johns Hopkins Bloomberg School of Public Health. He is also a trustee of the Hackensack (NJ) University Medical Center.  In March 2008, Mr. Ludwig ended a 2-year term as Chairman of the Advanced Medical Technology Association (AdvaMed), the world’s largest medical technology association.  He currently serves on the AdvaMed Board of Directors and chairs the Nominating and Governance Committee.  In the corporate arena, Mr. Ludwig serves on Aetna’s Board of Directors and chairs the Audit Committee.

Mr. Ludwig graduated from The College of the Holy Cross with a B.A. in Economics and Accounting and received his M.B.A. in Finance from Columbia University.  He is also a C.P.A.

Pharma and Biotech Panel


Moderator: Cliff Cramer
Director, Healthcare and Pharmaceutical Management Program 
Adjunct Professor, Columbia Business School

Mr. Cramer spent over 25 years as a senior professional in the financial services and healthcare/ pharmaceutical sectors.  He was Managing Director at Merrill Lynch and JP Morgan in their global healthcare investment banking groups, and Vice President, Corporate Planning & Development at Merck & Co., Inc., with worldwide responsibilities for strategic planning and business development.

Mr. Cramer’s previous experiences also include the co-founding of American Health Capital / VHA Enterprises, Inc., a healthcare/ financial services firm serving the capital needs of multi-hospital systems and other healthcare providers, and investment banking positions with Paine Webber, Inc. and L.F. Rothschild, Unterberg, Towbin, Inc.

Mr. Cramer is currently Director of the Healthcare and Pharmaceutical Management Program and Adjunct Professor at Columbia University, Graduate School of Business.  He teaches two courses in the spring semester: Strategy and Competition in Pharmaceuticals and Biotechnology, and Healthcare Investment and Dealmaking.


David Epstein (’87)
President and CEO, Novartis Oncology

David R. Epstein is President & CEO, Novartis Oncology.  In this position, he is responsible for leading Novartis’ global Oncology Business Unit, one of the world’s top Oncology companies with seven key marketed products – Glivec, Femara, Zometa, Sandostatin LAR, Exjade, Tasigna and Proleukin – and a leading pipeline recognized as exceptionally broad and deep. In 2007, Novartis Oncology’s sales grew 12.5% to $6.9bio and market share grew to 10.03%. 

Epstein currently oversees a staff of more than 5,000 employees operating in over 50 countries. He is a member of Novartis AG’s Pharma Committee and Pharmaceutical Executive Committee.

Epstein has held a series of positions of increasing responsibility since joining the company as a new product manager with Sandoz in 1989.  Epstein most recently served as CEO, Novartis Specialty Medicines, overseeing the global Ophthalmics and Transplantation & Immunology Business Units in addition to his responsibilities leading Novartis Oncology. He previously served as Chief Operating Officer of Novartis Pharmaceuticals Corporation in the U.S and has held several positions in marketing and general management.  During the planning process that resulted in the 1996 merger of Ciba-Geigy Ltd. and Sandoz Ltd., Epstein co-chaired the U.S. and Canadian Pharma Steering Committees as the Integration Officer, North America.  In January 1997, he was promoted to Vice President, Marketing and Sales, Specialty Business Sector, responsible for U.S. business units focused on Oncology and Transplant/Immunology/Tissue Engineering.  Prior to joining the company, he was an associate in the Strategy Practice of consulting firm Booz, Allen and Hamilton.

Epstein holds a B. S. degree in Pharmacy with high honors from Rutgers University College of Pharmacy and an M.B.A. in Finance and Marketing from the Columbia University Graduate School of Business. 


Kristin Peck ('99)
SVP Worldwide Strategy and Innovation, Pfizer

Kristin Peck is Senior Vice President, Worldwide Strategy and Innovation for Pfizer Inc.  In this role, Kristin is responsible for leading the team that develops, enables and monitors the long term strategic plan for Pfizer in order to drive profitable growth and deliver superior total shareholder return as well as leading the company-wide efforts to accelerate innovation and business model change. 

Kristin’s team led the development of Pfizer’s strategic path forward launched in 2007 and a global operating model review in 2008.  In the rapidly changing global healthcare environment, Worldwide Strategy and Innovation is continuously focused on identifying transformational business opportunities that extend and enhance Pfizer’s existing capabilities and achieve substantial revenue impact..

Kristin joined Pfizer in 2004 as Senior Director, Strategic Planning and was appointed to the role of Chief of Staff to the Vice Chairman in 2006 with responsibility for aligning and coordinating strategies, priorities and transformation activities across all groups in the Office of the Vice Chairman.  Kristin was promoted to Vice President, Strategic Planning in 2007 before moving into her current role in 2008.

Kristin is a member of the East Coast Executive Board for the Center for Corporate Innovation and the Chief Strategy Officer Roundtable.  Kristin was a recipient of the 2005 Upjohn Award for her “Focus on Performance”.

Prior to joining Pfizer, Kristin was a Manager with the Boston Consulting Group (BCG) for five years, focusing on strategy and merger-related issues in the pharmaceutical and financial services industries. Before BCG, Kristin worked in private equity and real estate finance at The Prudential, the O’Connor Group and J.P. Morgan.  Kristin holds a Bachelor’s degree from Georgetown University and an MBA from Columbia Business School.  Kristin and her husband Bob live in Connecticut with their two young children and dogs.


Steve Marlin, PhD
VP, US Pharma Partnering and Alliance Management, Boehringer Ingelheim

Steve Marlin is the Vice President, U.S. Pharma Partnering and Alliance Management for Boehringer Ingelheim Pharmaceuticals, Inc.

Dr. Marlin began his career with Boehringer Ingelheim in 1987 in R&D as a drug discovery researcher.  After a 10 year career in R&D which included increasing responsibilities as a researcher, lab manager, and project leader, Dr. Marlin took a position in Business Development, leading to his current position.

He received a Bachelor’s degree in Microbiology from DePauw University, a Ph.D. in Cellular and Molecular Biology from The University of Michigan, and was a Research Fellow at Harvard University (Dana-Farber Cancer Institute).


Thomas Nee
VP, New Products, Forest Laboratories

Thomas Nee is the Vice President, New Products, Marketing for Forest Laboratories, Inc., based in New York. This team guides the commercial evaluation and management of all potential products for Forest’s present and future pipeline. The department is comprised of a number of talented individuals who possess the business, scientific, and marketing acumen necessary to form the market insights for Forest’s pipeline acquisitions.  Importantly, New Products at Forest is constantly innovating in order to anticipate and envision the future pharmaceutical market landscape.

Thomas joined Forest in 1990 and has held positions of increasing responsibility in the marketing department. Over his career at Forest, he has led product management groups in various therapeutic categories, the marketing research group, and, most recently, created the New Products group. His experience encompasses product and company acquisitions, product launches, product lifecycle management, and generic business management.  Prior to joining Forest, he worked in health care marketing at the Procter and Gamble Company, Cincinnati.  Thomas holds a Bachelor’s degree from the University of Santa Clara and an MBA degree from Stanford University.


Michael Aberman, MD
Vice President, Credit Suisse

Michael Aberman is the lead US Biotech analyst at Credit Suisse where he covers both large and small cap biotech companies. Prior to joining Credit Suisse, Mr. Aberman covered small-cap biotech companies at Morgan Stanley. Prior to moving to Wall Street, he was the director of Business Development for Antigenics, a small cap biotech company.

Mr. Aberman received his medical degree from University of Toronto, completed his residency in internal medicine at NewYork-Presbyterian Hospital, and received his MBA from Wharton.

Medical Devices and Diagnostics Panel:


Holly Sheffield ('97)
Managing Director, Credit Suisse

Holly is a Managing Director and Global Head of the Medical Device Investment Banking practice with 15 years of Healthcare Investment Banking experience.  She joined Credit Suisse following the merger with Donaldson, Lufkin & Jenrette in 2000, joining DLJ in 1997.  She is also co-chair of the Credit Suisse Investment Banking Diversity Advisory Council.  Holly received her MBA from Columbia Business School and her BS from Cornell University.


Luke Sarsfield
Managing Director, Global Head of Medical Devices, Goldman Sachs

Luke is global head of the medical device investment banking practice.  He joined the firm’s Healthcare Group in 1999 and served as the group’s business unit manager in 2002. He was
named managing director in 2007. Prior to joining Goldman Sachs, Luke was a consultant for McKinsey & Co. and a healthcare investment banker at Credit Suisse First Boston.

Luke is vice chair of the Board of Directors of Literacy, Inc., a New York City-based nonprofit focused on promoting early childhood literacy. Luke received his MBA from Harvard Business School and his BA in Anthropology, magna cum laude, from Harvard College.


Bruce Cranna
Managing Director, Medical Supplies and Devices, Leerink Swann

Bruce Cranna joined Leerink Swann in 2002 to focus on diversified medical supply and diagnostic companies. Mr. Cranna was recently ranked #2 by the Wall Street Journal in its 2008 “Best on the Street” analysts’ survey and earned a #1 ranking by the Financial Times in its 2008 “World’s Best Analysts” special report.

Previously, Mr. Cranna was Director and Senior Analyst in Equity Capital Markets at ABN AMRO, where he was a Wall Street Journal All-Star in 2000 and 2004, and a top-ten ranked analyst in the Reuters U.S. 2000 and 2001 Surveys. Prior to ABN AMRO, Mr. Cranna served as Vice President, Equity Capital Group at The Chicago Corporation. He also held the position of Senior Consultant at the former Coopers & Lybrand for three years, in that company's Healthcare Financial Services Group. In addition, Mr. Cranna served as Senior Analyst, Contract Financial Management Department of Blue Cross and Blue Shield of Massachusetts.

Mr. Cranna received his MBA in Finance, Cum Laude, from Northeastern University and his B.A. in Economics, Cum Laude, from the University of Massachusetts, Amherst.


Toshie Davis
Director, Business Planning and Operations
Cordis Corporation, a Johnson and Johnson Company

Toshie Davis joined Cordis Corporation in April 2008 as the Director of Business Planning & Operations and has been with Johnson & Johnson since 2003.  During her time at J&J, Toshie has held roles of increasing responsibility in both the Medical Device and Pharmaceutical segments of the company.  She began at Ethicon Women’s Health & Urology franchise where she held the position of Worldwide Finance Director supporting the launch of five new products, the charter of six R&D development projects.  She helped to drive investment and growth in strategic umbrella markets and facilitated pricing initiatives.  As the Finance Director at Health Care Services, Toshie supported the sales and marketing teams that called on Managed Care Organizations, PBMs, GPOs and major hospital groups.
Toshie has over 17 years of professional experience in financial analysis and strategic business planning. Prior to joining Johnson & Johnson, Toshie spent most of her career in financial services where she worked in mergers and acquisitions and investor relations.

A graduate of the University of Pennsylvania with a degree in Economics, Toshie also holds an MBA from The Kellogg School of Management, Northwestern University.


Lothar Krinke, PhD
Vice President, Research and Business Development, Medtronic Neuromodulation

Dr. Krinke is Vice President Business Development for Medtronic Neurological. Previously, he was Vice President Business Development and Executive Team member of Endogeny Bio Corporation. He also was Vice President Business Development and Strategic Planning at Celera Genomics. Dr. Krinke has over 10 years of biomedical strategy expertise from two top management consulting firms: A.T. Kearney, where he was a Vice President, and McKinsey & Company.

Dr. Krinke completed his postdoctoral training as an American Cancer Society Fellow at the California Institute of Technology. He holds a Ph.D. in Molecular Biology from the University at Albany and obtained his undergraduate education at the Technische Univeritaet Braunschweig in Germany. He is the recipient of the Rumbough Award for Dedication to and Achievements in Diabetes research from the Juvenile Diabetes Research Foundation International.


Cathy T. Doherty
Vice President, Hospital Services, Quest Diagnostics Incorporated

Payor and Provider Panel


Moderator: Linda V. Green, PhD
Armand G. Erpf Professor, Columbia Business School

Linda V. Green is the Armand G. Erpf Professor at Columbia Business School. She earned her doctorate in Operations Research from Yale University. Her research, which has focused on the development and application of mathematical models of service systems, has resulted in dozens of publications in the major technical journals including Operations Research, Management Science, and The Journal of Applied Probability as well as prominent healthcare journals such as Health Services Research, Inquiry and Academic Emergency Medicine. Her early work led to the development of a model for the dispatching and allocation of emergency vehicles which became the foundation for a patrol car allocation model that is used by many major cities in the U.S. as well as several other countries. Her current research is on identifying operational policies to improve the delivery of healthcare. Specific projects focus on improving emergency responsiveness, developing strategies for the efficient and effective use of major diagnostic equipment such as MRIs, providing timely access to primary care, and the development of a new nurse staffing methodology. She is a co-founder and co-director of the Columbia Alliance for Healthcare Management, a unique partnership of the College of Physicians and Surgeons, the Mailman School of Public Health and the Business School of Columbia University dedicated to promoting interdisciplinary research and education in healthcare management. She has been a consultant for both private and public sector organizations and has served on several advisory boards. She has served in many administrative positions at both Columbia and in the major professional societies and is currently the Department Editor for Public Sector Applications for the journal Management Science. In recognition of her professional achievements, Professor Green was elected a Fellow of INFORMS, the premier international professional society for operations research and management science.


Alan Muney, MD
Executive Director, Private Equity, Blackstone Group; former CMO Oxford Health

Alan Muney is an Executive Director in the Corporate Private Equity group and the CEO of Equity Healthcare, Blackstone's proprietary healthcare services group purchasing organization. He is based in New York. Dr. Muney is involved in portfolio management and monitoring of healthcare benefits.

Before joining Blackstone, Dr. Muney was the executive vice president and chief medical officer of Oxford Health Plans and chief medical officer of United Healthcare of the Northeast region from 1998-2007. Prior to that, he was senior vice president and chief medical officer for Avanti Health systems, a division of NYLCare health plans. He was also regional medical director for Mullikin Medical Centers, a large multi-specialty medical group in California. In these positions, Dr. Muney had responsibility for business development, restructuring, utilization, quality and disease management programs, employer health benefit design strategies, and external relationships with providers, regulators, and the media. He is a frequent lecturer on issues in managed health care.

Dr. Muney received his BS in Biology and his Doctor of Medicine degrees from Brown University, and a Masters in Health Administration from the University of La Verne. He is on the Board of Directors of Vanguard Health System and Team Health.


Amitabh Chandra
Assistant Professor of Public Policy, John F Kennedy School of Government, 
Harvard University

Amitabh Chandra is a professor of public policy at the Harvard Kennedy School of Government. He is a Faculty Research Fellow at the IZA Institute in Bonn, Germany, and at the National Bureau of Economic Research (NBER) in Cambridge, Massachusetts. His current research focuses on the role of medical malpractice litigation on the delivery of health care, and the economics of neonatal health and cardiovascular care, and technology and expenditure growth in healthcare. His research has been published in the American Economic Review, the Journal of Political Economy, the Journal of Labor Economics, Journal of Policy Analysis and Management, and Health Affairs. He is an editor of the Journal of Human Resources, the American Economic Journal and Economics Letters. 

He has been a faculty member at Dartmouth and MIT, and has been a consultant to the National Academy of Science, the Robert Wood Johnson Foundation, and the RAND Corporation. He is the recipient of an Outstanding Teacher Award, the Arrow Award for the best paper in health economics, the Eugene Garfield Award for economic research that impacts medicine, and is the first-prize recipient of the Upjohn Institute's International Dissertation Research Award.


Karen Scott Collins, MD, MPH
Vice President, Quality and Patient Safety, New York-Presbyterian Hospital

Dr. Karen Scott Collins joined NewYork-Presbyterian Hospital in August 2007 as Vice President for Quality and Patient Safety. In this position, she is responsible for developing and leading clinical quality improvement and patient safety work across the five hospital campuses of the Columbia and Cornell Medical Schools. Immediately prior to this role, she served as Deputy Chief Medical Officer, New York City Health and Hospitals.  Prior to joining HHC, Dr. Collins was Vice President at the Commonwealth Fund, responsible for developing the Fund’s program on Quality of Care for Underserved Populations. 

Dr. Collins has published articles and reports on trends and experiences with managed care, women’s health, adolescent health and minority health.  She is the co-editor of two books, Women’s Health: The Commonwealth Fund Survey, and Minority Health in America, both published by Johns Hopkins University Press.  In April 2002, Dr. Collins received the Healthcare Hero Award from the Congressional Black Caucus.
Dr. Collins graduated from Harvard University with a degree in History of Science.  She received her Doctor of Medicine from Cornell University Medical College and an M.P.H. from the Bloomberg School of Public Health at Johns Hopkins University.  


Andrew Davis 
Vice President, Senior Market Development, Medco Health Solutions, Inc.

Andrew Davis is Vice President, Senior Market Development at Medco Health Solutions.  Mr. Davis is accountable for Medco’s national Prescription Drug Plan for individuals and employer groups, developing and executing Medco's insured product growth strategy and distribution development and management plan for retirees and Medicare beneficiaries across multiple markets and group/individual solutions. Prior to assuming this role, Mr. Davis oversaw the national account business for UnitedHealth Group, a large managed care client supported by Medco. Prior to joining Medco in 2000, Mr. Davis was with Blue Cross Blue Shield of Minnesota, the Minnesota Department of Health and Human Services, and also worked on Capitol Hill for U.S. Representative James L. Oberstar.      


Jon Kaplan
Partner and Managing Director, Boston Consulting Group

Jon Kaplan is a Partner and Managing Director for The Boston Consulting Group. Mr. Kaplan joined BCG's Chicago office in 2007 and is a core member of BCG 's Health Care and Strategy Practice Areas.  Mr. Kaplan has been serving the health care industry for more than 20 years.  Prior to joining the firm, Mr. Kaplan was a Senior Partner for the firms of Accenture and Ernst & Young, focusing on all components of the health care industry.
Mr. Kaplan has assisted global health care clients in the payer, provider, diagnostic, imaging, equipment, Rx, solution and distribution fields, focusing on areas of competitive strategy, mergers & acquisitions, strategic planning and marketing, services development, operations improvement, technology architecture and planning, and post-merger integration.  
Mr. Kaplan graduated from Cornell University with an AB in economics.  He received his MBA from the Executive Program of Northwestern University's J.L.Kellogg Graduate School of Management, and holds an MPH in biostatistics from the University of Pittsburgh.  He has served on average over ten years on the Boards of Juvenile Diabetes Research Foundation, Arthritis Foundation and Junior Achievement.

Mergers and Acquisitions Panel


Gerald Adolph
SVP, Head of Mergers and Restructurings Group, Booz and Company

Gerald Adolph is a New York-based Senior Partner with Booz & Company with a specialty in strategy and operations for technology-driven businesses. Mr. Adolph's work primarily focuses on assisting clients with growth strategy, new business development, and industry restructuring. In support of his clients' growth agendas, Mr. Adolph has led M&A pre-deal assessments as well as multiple complex, challenging post-merger integration assignments.

Mr. Adolph is a former member of the firm’s Board of Directors, a past leader of the firm’s global chemicals business, and a former leader of the firm’s global consumer and health work. He currently leads Booz & Company’s work for mergers and restructuring clients. 

Mr. Adolph has received Booz & Company's Professional Excellence Award in recognition of his outstanding and innovative client service for Quest Diagnostics.  A thought leader in his field, he has also contributed articles to Strategy+Business, The Deal, Corporate, and CFO Magazine.

Mr. Adolph graduated from MIT with a BS in chemical engineering and management science/organizational psychology as well as a master’s degree in chemical engineering.  He received his MBA from Harvard Business School.


Ken Hitchner('92)
Managing Director, Head of Healthcare Investment Banking, Goldman Sachs and Co.

Ken Hitchner is head of Goldman Sach’s healthcare banking group. He joined the firm in 1992 as a member of the Corporate Finance Department. In 1995, Mr. Hitchner joined the healthcare group as a founding member. He became head of Goldman Sachs' global medical device banking practice in 1998 and the global pharmaceutical banking practice in 2001. Some of Mr. Hitchner’s current clients are Johnson & Johnson, Medtronic, Eli Lilly and GE Healthcare among others. He was named managing director in 2000 and partner in 2002. 

Prior to joining the firm, Mr. Hitchner was a lieutenant commander and naval aviator in the US Navy. He is a trustee and member of the Board of Meridian Health Systems, Monmouth University and The Rumson Country Day School. Mr. Hithchner graduated from the University of Colorado and received an MBA as a merit fellow at Columbia Business School.


Robbie Huffines
Managing Director, Head of Heathcare Investment Banking, JP Morgan Chase

Robert L. Huffines joined J.P. Morgan in 1992 and is currently co-head of the global healthcare investment banking group.  Mr. Huffines is primarily focused on medical device, pharmaceutical, and biotechnology clients.  Mr. Huffines has advised numerous healthcare companies on strategic transactions, including in 2008: Celgene's acquisition of Pharmion, Kinetic Concept's acquisition of LifeCell, Amgen's sale of Amgen K.K. to Takeda, Eisai's acquisition of MGI Pharmaceuticals, Takeda on its division and integration of the Takeda Abbott Products joint venture, Sirtis Pharmaceutical's sale to Glaxo SmithKline.

Prior to joining J.P. Morgan, Mr. Huffines worked at Alex Brown & Sons, specializing in equity financings and advisory assignments for emerging growth companies.

Mr. Huffines has an MBA degree from the University of Virginia, where he received the faculty award for academic excellence.  He has a B.A. degree from the University of North Carolina, where he majored in English and Economics.

Mr. Huffines is married and has four children.  His volunteer work includes The Brookings/Gates Global Health Innovative Financing Advisory Group, the Student Spponsor Partnership, and serving as a board member of the Spence School.  


Stuart Smith ('84)
Managing Director, Head of Heathcare Investment Banking, Credit Suisse

Stuart F. Smith is a Managing Director of Credit Suisse and Head of Health Care within the Investment Banking Department, based in New York.  

Prior to joining Credit Suisse First Boston in 1999, Mr. Smith was a Managing Director of Alex Brown & Sons and its successor firms. He has been involved in structuring numerous M&A transactions as well as effecting financings for clients across all sectors of the health care industry including: Express Scripts, Genzyme, IDX, King Pharmaceuticals and Lab Corp.

Mr. Smith graduated from Franklin and Marshall College and received a J.D. from the University of Connecticut School of Law and an MBA from Columbia Business School.


Dick Van Duyne
Global Head of Business Development, Daiichi Sankyo

Dick Van Duyne joined Daiichi Sankyo in 2003.  In his current position, he chairs the Senior Licensing Committee and works directly with senior management, in Tokyo and the US and Europe, on key licensing and business development projects. 

Prior to this role, Mr. Van Duyne was Senior Vice President of Corporate Development at Pharmacia Corporation, serving in that capacity until Pharmacia was acquired by Pfizer in 2003.  Prior to Pharmacia, Mr. Van Duyne was, for a brief time, co-founder of MedPointe, a specialty pharmaceutical company.  Previously, he was Vice President Licensing & Business Development at Warner-Lambert Company, where he worked for seventeen years until the company was acquired by Pfizer in 2000. 

Mr. Van Duyne graduated from the University of Pennsylvania with a BS Economics degree. He received his MBA from Wharton his J.D. from Stanford University.

Life Sciences Ventures Panel


Barbara Dalton, PhD
VP, Venture Capital, Pfizer

Barbara Dalton is Vice President of Venture Capital for Pfizer Inc.  She joined the company in 2007 with responsibility for growing Pfizer’s corporate venture activities.  Early in her career, Ms. Dalton pursued drug discovery research at SmithKline’s laboratories and joined their venture capital group in the early 1990’s. While there, Ms. Dalton founded EuclidSR Partners, a private New York based venture capital firm (SmithKline was a leading limited partner), and joined the firm in 2003.

Ms. Dalton has managed over 20 fund investments and 60 diverse company investments in the US and Europe and has had direct investing responsibility for biotechnology therapeutic and platform technology companies as well as healthcare IT and service businesses.

Ms. Dalton graduated from Pennsylvania State University and received a PhD from The Medical College of Pennsylvania, where she trained as a research scientist in virology. She currently serves on the Board of Directors for the Penn State Research Foundation and is advisor to the Dean of the Eberly College of Science.

Ms. Dalton also serves on the board of the New York Biotech Association, NYSTAR, NYCIF and the National Venture Capital Association.


Darren Carroll
Executive Director, New Ventures, Eli Lilly and Company

Mr. Carroll leads the New Ventures Division of Eli Lilly and Company which includes Lilly Ventures where he is the Senior Managing Director. Carroll is the founder of Lilly Asian Ventures, the first venture capital group of its kind in the pharmaceutical industry.  Prior to assuming his current role, Mr. Carroll was the founding chief executive officer of InnoCentive, Inc., the first e-business venture created by Lilly.  Among other positions Mr. Carroll has held at Lilly, he was the U.S. attorney for Prozac®.  

Mr. Carroll has also served as senior vice president of RealMed, a venture-backed company based in Indianapolis, which created the first real-time health claims adjudication system.  Earlier in his career, he practiced law with a large private law firm in New York and negotiated technology transactions for General Electric Company.

His education includes a J.D. degree from Syracuse University College of Law.  He also holds a bachelor's from Syracuse University (Phi Beta Kappa) and a masters of public administration degree from the Maxwell School of Syracuse, where he is a member of the Board of Advisors.  He is also a member of the Board of Directors for Lilly Ventures and Lilly Asian Ventures portfolio companies including Citic Pharmaceuticals, Hydra Biosciences, InnoCentive and GlobeImmune, and is chairman of the advisory board for the Indiana Future Fund.


Ron Hunt
Managing Director, New Leaf Venture Partners

Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on investments in biopharmaceuticals and laboratory infrastructure companies. Ron joined the Sprout healthcare team in January 1998, and was part of the team that spun out of the Sprout Group (the venture capital affiliate of Credit-Suisse) in 2005 to form NLV.

Prior to joining Sprout, Ron was a consultant with Coopers & Lybrand Consulting and then with The Health Care Group (a division of the Interpublic Group of companies) for a combined 4 years. His consulting work focused on strategic and operational engagements for clients in the pharmaceutical and medical device industries.

Prior to entering the consulting field, Ron held a number of sales and marketing positions for a combined 8 years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Ron is a graduate of The Wharton School (MBA) and Cornell University (BS). Ron was the lead investor and served on the boards of Cerexa, Inc. and Aspreva Pharmaceuticals up until their recent acquisitions by Forest Laboratories and Gallenica Group, respectively. Ron has served on a number of other boards for companies in a broad range of healthcare sectors including biotech, laboratory services, health care information technology, and laboratory instrumentation.


Timothy Howe ('85)
Partner, CHL Medical Ventures

Tim has been investing in private equity since joining Schroder Ventures in 1984. He has been an active investor and board member responsible for numerous venture investments in the biotechnology, medical device and healthcare services areas, including Innotech, Inc. (acquired by Johnson & Johnson), Camitro Corporation (acquired by ArQule, Inc.), and Alexion Pharmaceuticals, Inc.

Tim also played a leading role in the formation of Biotechnology Investment Group, L.L.C., which took over a portfolio of equity investments in many financially distressed biotechnology companies. Tim was instrumental in working with these portfolio companies in arranging financings, mergers, and ultimate successful realizations.

Tim has been a director of nineteen companies and is currently on the boards of Bionaut Pharmaceuticals, Inc., Comprehensive NeuroScience, Inc., Medicus Insurance Holdings, Inc. and MedMark Services, Inc. He is also an Adjunct Assistant Professor at Columbia Graduate School of Business teaching venture capital management. Tim is a graduate of Columbia College and the Columbia Graduate School of Business.


Harri Taranto ('80)
Managing Director, Symphony Capital

Mr. Taranto co-founded Symphony in 2002 and has more than 25 years of experience advising investors and management teams of pharmaceutical, biotechnology and related healthcare companies.  Prior to joining Symphony, he was a Managing Director and co-founder of Wilkerson Partners, a healthcare and life sciences strategy consulting firm. 

Previously, Mr. Taranto was a co-founder and partner, for 17 years, with The Wilkerson Group and its successor, TWG/IBM Healthcare Consulting, where he was head of the Global Pharmaceutical practice.  Throughout his TWG/IBM career, he was instrumental in shaping strategy and investment opportunities for leading biopharmaceutical companies and private equity investors.  His clients have included industry leaders and emerging growth-stage companies, as well as private equity investment firms.  Prior to joining TWG, Mr. Taranto was a consultant with McKinsey & Company from 1980 to 1983. 

He earned an M.B.A. in Finance from Columbia University and received his B.S. in Electrical Engineering from Yale  University.  Mr. Taranto is a director and Chairman of Symphony Evolution, Inc. and Symphony Dynamo, Inc., and a director of Symphony Allegro, Inc., all Symphony portfolio companies.  In addition, Mr. Taranto serves on the Business Council of Solera Capital LLC, the Board of Directors of MIQS, Inc. and the Advisory Board of Doctors of the World-USA.


Joseph Gulfo, MD
President and CEO, Director, Electro-Optical Sciences, Inc.

Joseph V. Gulfo, M.D., M.B.A. has served as President and Chief Executive Officer and a member of Electro-Optical Sciences board of directors since January 2004. From May 1999 to November 2004, he served as Chairman, Chief Executive Officer and President of Antigen Express, Inc., a development-stage company developing immunodiagnostics and therapeutics for cancer. Previously, he was Chief Operating Officer and a Director of Anthra Pharmaceuticals, Inc. and Chairman of that company's UK subsidiary.

Dr. Gulfo serves as a director of ProCertus BioPharm, Inc., a privately-held company. Dr. Gulfo received a B.S. in Biology from Seton Hall University, an M.D. from the University of Medicine and Dentistry of New Jersey and an M.B.A. in Finance from Seton Hall University.

Emerging Markets Panel


Frank R. Lichtenberg, PhD
Courtney C. Brown Professor of Business
Columbia Universtiy Graduate School of Business

Frank R. Lichtenberg is Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business, and a Research Associate of the National Bureau of Economic Research.  He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.  

Professor Lichtenberg previously taught at Harvard University and the University of Pennsylvania.  He has served as an expert for the Federal Trade Commission, the U.S. Dept. of Justice, and state Attorneys General, and has testified before Congress.  He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau, and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich, and elsewhere.  

Some of Professor Lichtenberg’s research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. Recently he has performed studies of the impact of pharmaceutical innovation on longevity, the effect of computers on productivity in business and government organizations, and the consequences of takeovers and leveraged buyouts for efficiency and employment.  His articles have been published in numerous scholarly journals and in the popular press.  His book Corporate Takeovers and Productivity has been published by MIT Press.  He was awarded the 1998 Schumpeter Prize for his paper, Pharmaceutical Innovation as a Process of Creative Destruction, and a 2003 Milken Institute Award for Distinguished Economic Research for the paper, Pharmaceutical Knowledge-Capital Accumulation and Longevity.

He has been awarded research fellowships, grants, and contracts by the National Science Foundation, the National Institute of Standards and Technology, Merck and Co., the Fulbright Commission, the Brookings Institution, the Alfred P. Sloan Foundation, The German Marshall Fund, the American Enterprise Institute, and other organizations.  He has served as a consultant to private organizations and government agencies including the Securities Industry Association, Pfizer, Inc., the Community Preservation Corporation, the RAND Corporation, the New York City Water Board, Touche Ross and Co., The Walt Disney Company, McGraw-Hill, and the National Pharmaceutical Council. He is an Affiliate of the economics consulting firm LECG, LLC.


Sanjay Behl
Partner, Deloitte Consulting

Sanjay Behl is a Principal in the Strategy & Operations practice at Deloitte Consulting. Mr. Behl brings over ten years of experience in consulting for global pharmaceutical companies on a range of business issues, from manufacturing and supply chain optimization to revenue enhancement to organizational redesign.  Before coming to Deloitte, Mr. Behl was involved with development in the chemical industry, first as a Senior Development Engineer at Engelhard Corporation and then as Business Development Manager at Cabot Corporation, both chemical companies with global operations.

Mr. Behl has been issued 12 US patents and has published 19 international journal articles as well as five book chapters. He has also been a thought leader at Deloitte on “Sales Force Productivity and Effectiveness” in a pharmaceutical company and “Future of Mergers and Acquisition Strategy” in the pharmaceutical industry.

Mr. Behl graduated the Indian Institute of Technology with a B.Tech before pursuing an M.S. in Chemical Engineering at Syracuse University.  He went on to receive a Ph.D. in Materials Science and Engineering at the University of Florida and also earned an MBA from INSEAD.


Nils Daulaire, MD, MPH
President and CEO, Global Health Council

Dr. Nils Daulaire is president and CEO of the Global Health Council, the world’s largest membership alliance of public health professionals and organizations working in over 100 low-income countries, and dedicated to raising the attention, resources, and knowledge needed to improve health worldwide.  He served in the 1990s as USAID’s Deputy Assistant Administrator for Policy and was the U.S. government’s Senior International Health Policy Advisor, serving as negotiator at numerous international conferences. 

Previously he worked for two decades on developing and managing maternal and child health services in developing countries, and on field research to identify and validate effective and high-impact health interventions to reduce child deaths.  

A Phi Beta Kappa and summa cum laude graduate of Harvard College, he received his M.D. from Harvard Medical School and his Master’s in Public Health from Johns Hopkins University.  He is a member of the National Academy of Science’s prestigious Institute of Medicine, testifies frequently before Congress, and has appeared widely in the national and international media on global health issues.


Andy Pasternak
Partner, Bain & Company

Andy Pasternak is a partner in Bain’s Healthcare Group, based in Chicago. Prior to joining Bain in 2008, Andy was a partner in the Health & Life Sciences Practice at Oliver Wyman, a global management consultancy.

During his 10+ years at Oliver Wyman (formerly named Mercer Management Consulting), Andy served clients in the pharmaceuticals and biotechnology arena, and also conducted work in the global health space with organizations such as the Bill & Melinda Gates Foundation, WHO, UNICEF and the GAVI Alliance. Andy has conducted extensive strategy work for both private sector and public sector clients to address access issues for life-saving pharmaceutical products in emerging markets and in the developing world. Andy has particular expertise in the areas of vaccines and infectious diseases, in which he is an internationally recognized strategy consultant.

Prior to joining Oliver Wyman, Andy worked in the Corporate Finace Group of J.P. Morgan Securities. Andy earned an M.B.A. from the University of Chicago Graduate School of Business, and a B.A. in Economics from Northwestern University. He resides in the Chicago area with his wife Susan and his three children.


Eric T. Rothstein
Senior Director, Strategy Development & Realization
Merck Vaccines and Infectious Diseases

Eric Rothstein is the Senior Director of Strategy Development and Realization for Merck's global vaccine and infectious diseases business.  He is responsible for developing strategies that cut across Merck's pediatric, adolescent and adult vaccine and infectious disease franchises, which include brands such as Gardasil®, RotaTeq®, Zostavax®, Invanz® and Isentress®.  Eric's current area of focus is on determining Merck's approach for vaccines and infectious disease products in emerging or under-penetrated markets, including China, India, Brazil, Korea, Russia, Turkey and Poland.

Eric joined Merck in 1989 as part of the Merck Manufacturing Division and has spent the last 12 years in positions of increasing responsibility in sales, market research and marketing, working on such brands as Singulair®, Fosamax®, and Propecia®.

Eric is the recipient of numerous sales, marketing and leadership awards including the Vice President's Club Sales Award and Marketer of the Year.

Eric holds a Bachelor of Science Degree in Mechanical Engineering from the University of Connecticut and a Masters of Business Administration from Rutgers Graduate School of Management.

Eric lives in Pennsylvania with his wife and their 2 sons.  In his spare time he trains and competes in endurance events and has completed multiple marathons, triathlons and charity bike tours.


Bhaven N. Sampat, PhD
Assistant Professor, Columbia University

Bhaven Sampat, PhD, is an assistant professor in the Department of Health Policy and Management and (by courtesy) in the School of International and Public Affairs at Columbia University. An economist by training, Sampat is centrally interested in issues at the intersection of health policy and innovation policy. His current projects examine the impacts of new global patent laws on innovation and access to medicines in developing countries, the political economy of the National Institutes of Health, the roles of the public and private sectors in pharmaceutical innovation, and institutional aspects of patent systems. Dr. Sampat has also written extensively on the effects of university patenting and "entrepreneurship" on academic medicine, and is actively involved in policy debates related to these issues.

Dr. Sampat was previously an Assistant Professor at the School of Public Policy at Georgia Tech, and a Robert Wood Johnson Foundation Scholar in Health Policy Research at the University of Michigan." He is recipient of a Robert Wood Johnson Foundation "Investigator Award" to study how the NIH allocates its funds across disease areas. He is also principal investigator on a Ford Foundation initiative examining patent policy in developing countries, and director of the Columbia-Stanford Consortium on biomedical innovation.

Career Strategies Panel


Regina Resnick
Assistant Dean & Managing Director, Career Management Center
Columbia Universtiy Graduate School of Business

Gina joined the administration at Columbia Business School in 1996, in 1999 was named Assistant Dean & Director of the Office of MBA Career Services and Managing Director in 2005. The Office, renamed the Career Management Center in 2007, serves over 1400 full-time MBAs and 600 Executive MBAs, maintains a career management library and related student and recruiter web sites, offers one-on-one and group advising sessions and presents a wide variety of career management workshops. For 14 years, the Office has organized and hosted the Chazen International MBA Career Services Conference, addressing the key issues faced by international MBA career advisors.

As Managing Director, Gina oversees a team of employer relations specialists and career education and advising professionals. She both counsels students in all aspects of career development and the job search and works with corporations and other MBA hiring organizations to help them develop recruiting strategies. Gina and her team conduct extensive outreach efforts to encourage additional companies to recruit Columbia Business School students. Gina speaks frequently at various educational and corporate recruiting conferences. She was a 1998 recipient of The Robert W. Lear Award for extraordinary commitment to the student body.

Prior to coming to Columbia, Gina was a Partner at the advertising and communications firm Bozell Worldwide. During her 12 years at the firm, she worked with a variety of clients including Avis, Pfizer, Merrill Lynch and Joseph E. Seagram & Sons. Her initial assignment in advertising was on the Procter & Gamble account at Saatchi & Saatchi. Directly out of college, Gina was a research assistant for economic advisors to President Carter.


Stephen Israel
Managing Director, Biotechnology & Pharmaceuticals, Korn/Ferry

Stephen Israel is Managing Director, Biotechnology & Pharmaceuticals for Korn/Ferry’s North American Healthcare Practice. His practice group includes a team of industry experienced consultants who serve the unique recruiting needs of biotechnology, pharmaceutical and life sciences companies at all stages of development.

Having successfully conducted hundreds of executive recruiting assignments in the life sciences, Mr. Israel is an acknowledged industry expert and consultant to venture-backed start-ups, emerging growth companies and global pharmaceutical companies. He has recruited many chief executive officers, heads of research and development and general management of all functions.

Prior to returning to Korn/Ferry, where he established the life sciences practice, Mr. Israel served as Chief Administrative Officer for Cytel Corporation, a biopharmaceutical company in San Diego. Mr. Israel is originally from North Carolina and holds a Bachelor of Arts Degree from the University of North Carolina at Chapel Hill.


Richard Lipstein
Partner and Managing Director, Financial Services, Boyden Global Executive Search

Richard G. Lipstein is Partner and Managing Director in Boyden Global Executive Search’s Financial Services Practice.
A veteran search professional with twenty years of experience, Mr. Lipstein previously spent almost a decade in the corporate sector and on Wall Street.
As a member of the global Financial Services practice, Mr. Lipstein is well recognized for his record of achievement placing professionals in a broad range of functional and product areas.

Prior to becoming an Executive Search Consultant, Mr. Lipstein was a financial executive with the American Broadcasting Companies and an investment banker at the media industry M&A boutique Henry Ansbacher Inc.  

He is a graduate of the City University of New York (Brooklyn College; BA, Economics) and received an MBA with Distinction from Pace University Lubin School of Business.

Mr. Lipstein is currently Chairman of the Career Development Committee of the New York Society of Security Analysts (NYSSA).  He recently received a Volunteer of the Year Award for his contribution to this 11,000+ professional organization.  He has produced and moderated numerous NYSSA seminars on current events and relevant trends in the profession.

Mr. Lipstein is regularly quoted in the media, including, among others, The Wall Street Journal, Business Week, Institutional Investor, Bloomberg, and Investment Dealers Digest.


Denise Peppard
SVP, Human Resources, Wyeth

Denise Peppard is Senior Vice President, Human Resources, Wyeth.  In this role, she has responsibility for Wyeth's global human resources function, which includes human resources policies; employee pay and benefits programs; labor relations and employment matters; leadership development and training; employee diversity programs; talent management planning and executive recruitment.

Ms. Peppard is a member of the Wyeth Management Committee, the Human Resources and Benefits Committee, Law/Regulatory Review Committee and Operations Committee.  She also leads the HR Management Committee.  Ms. Peppard has focused her efforts on facilitating change in the business and redefining the role of Human Resources in Wyeth through an increased business orientation and consultative focus.

Ms. Peppard joined Wyeth-Ayerst (now Wyeth Pharmaceuticals) in 1999. Prior to joining the Company, she worked as Senior Director, Organization Development and Training at Parke-Davis in Ann Arbor, Michigan and as Vice President of Human Resources at Cyto Therapeutics, a small biotechnology company in Rhode Island.  In addition, she has worked as an internal consultant in the computer and financial services industries.  

Ms. Peppard received her MBA from the University of Michigan with a dual concentration in Organizational Behavior and Finance.


Gustavo Alba
Head of North America Recruiting, Booz and Company

Gustavo Alba is a Director with Booz & Company and leads their recruiting activities.  In this role, he is responsible for both experienced and campus hiring channels.  He is based in New York.

During his tenure at Booz & Company, Gustavo developed the North America experienced hire channel and facilitated a rapid scale up of Booz & Company’s European offices.  Recently, he successfully led the global recruiting activities for an entirely new career model called Design.  Prior to joining Booz & Company, Gustavo was responsible for building a full service global recruiting function at Neoris, a division of Cemex.

Gustavo has more than 10 years experience leading human capital initiatives focused on talent acquisition strategies and building world class recruitment organizations.  He has developed an expertise within the professional services market.


Wendy Suter
VP, Talent Management and Acquisition, Pfizer

Wendy Suter recently joined Pfizer in July 2008 as Vice President of Talent Management and Acquisition with responsibility for creating greater business value through talent by driving world-class talent management and acquisition processes to insure Pfizer is able to attract, retain and develop key talent. She joins the Worldwide Talent and Organization Capability team (WTOC) which collectively is focused on building the capability of the Pfizer organization to be high-performing and adaptive by developing leaders, managers and colleagues with the capabilities needed to deliver business results now and in the future AND enabling an organization culture that unleashes these capabilities.  

Wendy is a dynamic professional with 15 years of experience driving organizational change across varied industries and diverse organizational cultures and functions.  Examples of her areas of expertise include: Talent Management, Leadership and Organizational Development, Strategic Planning and Execution, and Competency Profiling among others.

Prior to joining Pfizer, Wendy was Executive Director of Leadership Development at Novartis Pharmaceuticals Corporation and was responsible for Leadership Development, Talent Management and Organizational Development.  She spent 7 ½ years in various HR roles at Novartis and provided support to the Development, Sales, Marketing, IT and Finance functions.  Prior to Novartis, Wendy was leading OD and Talent Management initiatives in support of the CMO of AlliedSignal/Honeywell to develop marketing capabilities necessary to drive growth.  She has also provided internal consulting services to Phillip Morris USA, Liz Claiborne, and Arthur Andersen. Wendy earned a Bachelor of Arts in Social Relations from Lehigh University, a Masters of Arts in College Student Personnel and Masters in Organizational Development from Bowling Green State University.

In her spare time, Wendy likes to ski, travel, and spend time with her nieces and nephew.

© 2008 Columbia Business School :: Healthcare Industry Association